Abstract
Magnetically responsive nanoparticles (MNPs) might be candidates for pro-drug formulations for intraperitoneal (i.p.) treatment of ovarian cancer. We conducted feasibility experiments in an i.p. human ovarian carcinoma xenograft model to determine whether MNPs can be effectively vectored within this environment. Our initial results based on magnetic resonance imaging (MRI) indicate that i.p.-injected ∼15 nm magnetite-based MNPs can in fact migrate toward NdFeB magnets externally juxtaposed to the peritoneal cavity above the xenografts growing in the anterior abdominal wall. MNP localization to the tumor/peri-tumoral environment occurs. Further development of this MNP pro-drug strategy is underway.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
